Landscape Capital Management L.L.C. Sells 108,088 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Landscape Capital Management L.L.C. trimmed its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 28.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 266,657 shares of the company’s stock after selling 108,088 shares during the period. Landscape Capital Management L.L.C. owned approximately 0.12% of Hims & Hers Health worth $4,912,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the last quarter. Quest Partners LLC grew its position in Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the last quarter. CWM LLC increased its holdings in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after buying an additional 1,054 shares during the period. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health in the second quarter worth $111,000. Finally, Amalgamated Bank raised its holdings in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after buying an additional 2,354 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 7.4 %

HIMS opened at $21.80 on Thursday. The stock has a market capitalization of $4.76 billion, a price-to-earnings ratio of 49.55 and a beta of 1.06. The firm has a 50 day moving average price of $20.21 and a 200-day moving average price of $19.09. Hims & Hers Health, Inc. has a twelve month low of $7.51 and a twelve month high of $30.44.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.04) earnings per share. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on HIMS shares. Bank of America lowered shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Imperial Capital cut Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Canaccord Genuity Group upped their price target on Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. TD Cowen reissued a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $20.71.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,339 shares of the stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total transaction of $38,593.50. Following the sale, the insider now owns 176,952 shares in the company, valued at approximately $2,919,708. This represents a 1.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Melissa Baird sold 58,750 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00. Following the transaction, the chief operating officer now owns 630,166 shares of the company’s stock, valued at $13,258,692.64. This trade represents a 8.53 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,056,183 shares of company stock valued at $21,501,682 in the last three months. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.